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BACKGROUND: Eisenmenger syndrome describes congenital heart disease-
associated severe pulmonary hypertension accompanied by right-to-left shunting. 
The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase 
III MAESTRO study (Macitentan in Eisenmenger Syndrome to Restore Exercise 
Capacity) evaluated the efficacy and safety of the endothelin receptor antagonist 
macitentan in patients with Eisenmenger syndrome.
METHODS: Patients with Eisenmenger syndrome aged ≥12 years and in World 
Health Organization functional class II–III were randomized 1:1 to placebo or 
macitentan 10 mg once daily for 16 weeks. Patients with complex cardiac defects, 
Down syndrome and background PAH therapy were eligible. The primary end point 
was change from baseline to week 16 in 6-minute walk distance. Secondary end 
points included change from baseline to week 16 in World Health Organization 
functional class. Exploratory end points included NT-proBNP (N-terminal pro-B-type 
natriuretic peptide) at end of treatment expressed as a percentage of baseline. 
In a hemodynamic substudy, exploratory end points included pulmonary vascular 
resistance index (PVRi) at week 16 as a percentage of baseline.
RESULTS: Two hundred twenty six patients (macitentan n=114; placebo n=112) 
were randomized. At baseline, 60% of patients were in World Health Organization 
functional class II and 27% were receiving phosphodiesterase type-5 inhibitors. 
At week 16, the mean change from baseline in 6-minute walk distance was 
18.3 m and 19.7 m in the macitentan and placebo groups (least-squares mean 
difference, -4.7 m; 95% confidence limit (CL), -22.8, 13.5; P=0.612). World Health 
Organization functional class improved from baseline to week 16 in 8.8% and 
14.3% of patients in the macitentan and placebo groups (odds ratio, 0.53; 95% 
CL, 0.23, 1.24). NT-proBNP levels decreased with macitentan versus placebo (ratio of 
geometric means, 0.80; 95% CL, 0.68, 0.94). In the hemodynamic substudy (n=39 
patients), macitentan decreased PVRi compared with placebo (ratio of geometric 
means, 0.87; 95% CL, 0.73, 1.03). The most common adverse events with 
macitentan versus placebo were headache (11.4 versus 4.5%) and upper respiratory 
tract infection (9.6 versus 6.3%); a hemoglobin decrease from baseline of ≥2 g/dL 
occurred in 36.0% versus 8.9% of patients. Five patients (3 macitentan; 2 placebo) 
prematurely discontinued treatment and 1 patient died (macitentan group).
CONCLUSIONS: Macitentan did not show superiority over placebo on the 
primary end point of change from baseline to week 16 in exercise capacity in 
patients with Eisenmenger syndrome.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT01743001.
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Eisenmenger syndrome (ES) is the most advanced form of uncorrected congenital heart disease- associated pulmonary arterial hypertension (PAH).1 
It can result from a wide range of congenital heart 
defects and is characterized by elevated pulmonary 
arterial pressure and resistance, and right-to-left in-
tracardiac or intra-arterial shunting with cyanosis.2,3 
Patients with ES have multiorgan sequelae and 
significantly premature mortality.3–8 For patients with 
ES who progress to World Health Organization (WHO) 
functional class (FC) III or above, disease progression is 
more rapid than for those in WHO FC II.4,8
A number of PAH therapies are used in clinical 
practice to treat patients with ES, including endothelin 
receptor antagonists (ERAs), phosphodiesterase type-
5 (PDE-5) inhibitors and prostanoids.9 However, the 
evidence supporting the use of these therapies in the 
ES population is limited, having been obtained from 
mostly small and uncontrolled or open-label studies.10–13 
To date, only the ERA bosentan has been investigated 
in a randomized, double-blind, placebo-controlled, 
multicenter study in patients with ES (BREATHE-5 
[Bosentan Randomized Trial of Endothelin Antagonist 
Therapy-5]).5 The study population consisted of 54 
treatment-naive patients with ES whom, at enroll-
ment, were restricted to WHO FC III, with anatomically- 
classified simple cardiac defects; bosentan was well 
tolerated and did not adversely affect oxygen saturation. 
Hemodynamics and exercise capacity were significantly 
improved by bosentan.5 ES patients with Down 
syndrome, who represent more than 25% of adult ES 
cohorts,14–16 and in whom data regarding efficacy 
of PAH therapy are particularly limited,17–21 were not 
included in BREATHE-5. As such, there exists a gap 
in assessment of therapy for patients with ES with a 
fuller range of real-world demographic characteristics 
than previously studied in BREATHE-5.5 The MAESTRO 
study (Macitentan in Eisenmenger Syndrome to Re-
store Exercise Capacity) was thus designed to address 
this need.
Macitentan, an ERA with sustained receptor 
binding,22 delayed disease progression in patients with 
PAH in the long-term SERAPHIN study (Study with an 
Endothelin Receptor Antagonist in Pulmonary Arterial 
Hypertension to Improve Clinical Outcome), as well 
as improving exercise capacity.23 SERAPHIN enrolled a 
broad range of PAH patients, including patients with re-
paired simple congenital systemic-to-pulmonary shunts 
at least 1 year postsurgical repair, but not patients with 
ES.23 The aim of the MAESTRO study was to evaluate 
whether macitentan improves exercise capacity in 
patients with ES with typical demographic characteristics 
(inclusive of patients with anatomically classified simple 
and complex congenital heart disease, WHO FC II and 
III, and not restricting enrollment based on chronic 
background therapy with PDE-5i therapy or presence of 
Down syndrome).
METHODS
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing the 
results or replicating the procedure.24
Study Design
The MAESTRO study (URL: www.clinicaltrials.gov. Unique 
identifier: NCT01743001) was a multicenter, double-blind, 
randomized, placebo-controlled, 16-week, phase III study. 
At certain centers, selected based on steering committee 
review of right heart catheterization expertise, patients were 
eligible to participate in a substudy that assessed exploratory 
hemodynamic end points by cardiac catheterization.
Clinical Perspective
What Is New?
• We report the results of the MAESTRO study 
(Macitentan in Eisenmenger Syndrome to Restore 
Exercise Capacity) which investigated macitentan 
in patients with Eisenmenger syndrome (ES).
• MAESTRO is the second randomized, double-
blind, placebo-controlled, multicenter study to 
investigate a pulmonary arterial hypertension 
therapy in ES patients.
• Macitentan did not show superiority over placebo 
on the primary end point of change from baseline 
to week 16 in exercise capacity; no relevant trends 
were observed for the secondary end points.
• Among the exploratory end points, macitentan 
reduced NT-proBNP (N-terminal pro-B-type natri-
uretic peptide) in the main cohort and improved 
pulmonary vascular resistance index and exercise 
capacity in the hemodynamic substudy.
• There were no specific safety concerns with 
macitentan use in ES patients.
What Are the Clinical Implications?
• Compared with the previous BREATHE-5 study 
(which investigated bosentan in ES patients), 
MAESTRO enrolled a more heterogenous 
population, including patients with simple or com-
plex cardiac defects, World Health Organization 
functional class II or III symptoms, and not 
restricting enrollment based on background 
therapy or presence of Down syndrome.
• MAESTRO therefore provides data on the use of 
pulmonary arterial hypertension therapy in 
ES patients with a wide range of real-world 
demographic characteristics.
• Furthermore, MAESTRO provides important insight 
into the conduct of future clinical studies of pulmo-
nary arterial hypertension therapy in ES patients.
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The study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice as outlined 
in the International Conference of Harmonization. Ethical 
approval was obtained from the relevant Institutional Review 
Board or Independent Ethics Committee for each participat-
ing center (refer to the online-only Data Supplement for more 
information). Written informed consent was obtained from 
all patients or a parent/legal representative and from the 
caregiver, where applicable. Additionally, written assent was 
obtained from all patients with Down syndrome and pedi-
atric patients who were unable to give written consent. The 
MAESTRO steering committee was involved in the design of 
the study, provided guidance on the study conduct, and mem-
bers reviewed screening data including all echocardiographic 
and cardiac catheterization data to corroborate the diagno-
sis of ES and confirm patient eligibility. An independent data 
monitoring committee reviewed the data on a regular basis 
during the trial in order to ensure patient safety. All authors 
had full access to the study data and take responsibility for 
the integrity of the data and the accuracy of the data analy-
ses. All authors were involved in the development and review 
of the manuscript.
Selection of Patients
Patients with ES who were aged ≥12 years were eligible 
for the main study, including patients with Down syndrome 
and those with anatomically-classified complex cardiac 
defects (excluding conotruncal defects, which refer to ven-
tricular outflow tract anomalies such as tetralogy of fal-
lot, truncus arteriosus or transposition of great arteries). 
Enrollment into the hemodynamic substudy was restricted 
to patients aged ≥18 years, with ES and simple atrial sep-
tal defects or ventricular septal defects, without Down 
syndrome. For the main study and the hemodynamic sub-
study, ES was established by echocardiography showing 
a large or nonrestrictive open congenital defect at atrial, 
ventricular or arterial level (isolated defect or in com-
bination) and right-to-left shunt or bidirectional shunt 
with prevalent right-to-left direction. Patients also had 
to have a resting oxygen saturation (SpO2) ≤90% and 
>70% and hemodynamic measurements of mean rest-
ing pulmonary arterial pressure >25 mm Hg, pulmonary 
artery wedge pressure or mean left atrial pressure or left 
ventricular end diastolic pressure ≤15 mm Hg, and pulmo-
nary vascular resistance (PVR) ≥800 dyn·sec/cm5 (10 Wood 
units). Cardiac catheterization must have been performed 
within 5 years prior to randomization or during the screen-
ing period for the main study and within 30 days prior to 
randomization for the hemodynamic substudy.
For both the main study and the hemodynamic substudy, 
patients were required to have symptomatic PAH in WHO FC 
II to IV and a 6-minute walk distance (6MWD) of 50 to 450 m, 
documented by 2 tests that did not differ by more than 15% 
performed during the screening period. For patients who had 
not previously performed a 6-minute walk test (6MWT), a 
practice test was requested before the qualifying walk test for 
inclusion; for patients with Down syndrome, at least 2 practice 
tests were required. PDE-5 inhibitors were allowed if the dose 
was stable for at least 1 month prior to randomization. Stable 
background therapy for other cardiopulmonary diseases (eg, 
antiarrhythmics, oral anticoagulants, digoxin, supplemental 
oxygen) was also allowed. Diuretics were allowed if the dose 
was stable for at least 1 week prior to randomization. Iron 
supplementation was allowed if initiated at least 3 months 
prior to randomization.
Patients were excluded from both the main study and the 
hemodynamic substudy if they had significant left ventricular 
dysfunction (ejection fraction <45%), previously recognized 
moderate-to-severe lung disease, conotruncal heart defects, 
severe tricuspid regurgitation or greater than mild tricuspid 
stenosis (as determined by site principle investigator or steer-
ing committee review), serum aspartate transaminase or ala-
nine transaminase greater than 3 times the upper limit of 
normal, iron deficiency (serum ferritin <10 µg/L), treatment 
by phlebotomy within 1 month prior to randomization, and 
treatment with ERAs or prostanoid(s) within 1 month prior 
to randomization. For the hemodynamic substudy, patients 
with certain congenital cardiac lesions (such as patent ductus 
arteriosus), where estimation of resting PVR was not read-
ily possible or reproducible with standard techniques, were 
excluded.
Study Procedures
Within 30 days of screening, eligible patients were randomly 
assigned in a 1:1 ratio to receive oral placebo or macitentan 
10 mg once daily for 16 weeks. Patient allocation to treat-
ment groups was initially stratified by location of the cardiac 
defect and participation in the hemodynamic substudy (n=87, 
44 macitentan, 43 placebo). Following a global protocol 
amendment, patients were stratified by WHO FC (II versus III/
IV), presence of Down syndrome (yes/no) and participation 
in the hemodynamic substudy (yes/no) (n=139; 70 maciten-
tan, 69 placebo). Randomization was based on a prespecified 
randomization schedule using randomization lists generated 
by an independent Contract Research Organization (Almac 
Clinical Technologies) and their centralized randomization sys-
tem, via an Interactive Voice Response System or Interactive 
Web Response System.
During the treatment period, patients were assessed at 
randomization, and at weeks 4, 8, 12 and 16. In the hemo-
dynamic substudy, cardiac catheterization was performed at 
screening and at the end of treatment (EOT) visit. EOT was 
at week 16 for patients who did not prematurely discontinue 
study treatment. For patients who did prematurely discon-
tinue study treatment, the EOT visit was performed whenever 
possible within 7 days after the last dose of study treatment; 
these patients also subsequently had a week 16 assessment. 
Adverse events were monitored throughout the treatment 
period and up to 30 days after EOT. Patients were considered 
to have completed the study if they completed the week 16 
assessments, regardless of whether or not they prematurely 
discontinued study treatment. Patients who completed the 
study were eligible to participate in the long-term open-label 
extension study, MAESTRO-OL (MAESTRO open-label; unless 
they had discontinued treatment due to an adverse event 
considered related to the study drug or due to liver enzyme 
elevations); all patients received macitentan 10 mg once daily 
in MAESTRO-OL (URL: www.clinicaltrials.gov. Unique identi-
fier: NCT01739400). Patients and sites remained blinded to 
their previous treatment allocation.
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Outcome Measures
The primary end point was change from baseline to week 
16 in 6MWD. Secondary end points, listed in the order of 
the prespecified testing hierarchy, included the change from 
baseline to week 16 in WHO FC and Borg Dyspnea index. 
Exploratory end points included the NT-proBNP (N-terminal 
pro-B-type natriuretic peptide) level at EOT expressed as a per-
cent of baseline and change in SpO2 from baseline to week 16 
(at rest and 0 minutes after performing a 6MWT). Safety end 
points included the evaluation of adverse events, laboratory 
abnormalities, and decreases from baseline in SpO2 >10% at 
rest, up to 30 days after study treatment discontinuation.
In the hemodynamic substudy, the following exploratory 
end points were assessed: indexed pulmonary vascular 
resistance index (PVRi) at week 16 expressed as a percent 
of baseline and absolute change from baseline to week 16 
in mean resting pulmonary arterial pressure, mean right 
atrial pressure, indexed pulmonary blood flow/indexed sys-
temic blood flow ratio, systemic vascular resistance index, 
and PVRi/systemic vascular resistance index. Additionally, 
posthoc exploratory end points of absolute change from 
baseline to week 16 in indexed pulmonary blood flow, 
indexed systemic blood flow, and 6MWD were evaluated.
Statistical Analysis
A sample size of 196 patients (98 per treatment group) 
had 90% power to detect a treatment difference in 6MWD 
between placebo and macitentan of 35 m with a standard 
deviation for the primary end point of 75 m, based on a 
2-sided significance level of 5% using the Student t test. 
It was planned to randomize 220 patients allowing for 
approximately 10% early drop out. Given the uncertainty 
of the variability for the primary end point in this patient 
population, an interim monitoring conducted on blinded 
data was planned and performed by the sponsor to check 
the assumptions of the sample size calculations. A blinded 
sample size re-estimation was performed, and it was rec-
ommended not to increase the sample size. Analyses for all 
efficacy end points were based on all randomized patients 
(full analysis set). Hemodynamic substudy analyses were 
performed on all patients in the full analysis set who 
participated in the hemodynamic substudy. Safety analyses 
were performed on all patients who received at least 1 dose 
of study treatment (safety analysis set).
For the analyses of 6MWD, the latest valid assessment 
from the 2 screening tests and the randomization test was 
taken as the baseline value. All available measurements at 
week 16 were used, irrespective of whether or not treatment 
was prematurely discontinued prior to week 16. The primary 
end point was analyzed by means of an analysis of covari-
ance (ANCOVA), including treatment group, Down syndrome 
(yes/no), baseline WHO FC (II versus III/IV) and baseline 
6MWD as covariates. Least-squares means and 2-sided 95% 
confidence limits (CLs) for the treatment effect between 
placebo and macitentan were estimated from the model. 
Prespecified and posthoc subgroup analyses were performed 
on the primary end point of change in 6MWD using interac-
tion tests to investigate heterogeneity of treatment effects 
across subgroups. To control for multiplicity, secondary end 
points were tested hierarchically according to a prespecified 
sequence. Improvement in WHO FC from baseline to week 
16 was analyzed by means of a logistic regression model, 
including the treatment group and location of cardiac 
defect as covariates. NT-proBNP was analyzed by means of 
an ANCOVA model on the log transformed ratio EOT/base-
line, including treatment group, location of cardiac defect 
and NT-proBNP baseline value (natural log scale) as covari-
ates. SpO2 was analyzed descriptively. For the hemodynamic 
substudy, PVRi was analyzed by means of an ANCOVA model 
on the log transformed ratio week 16/baseline, including 
treatment group, location of cardiac defect and baseline 
value (natural log scale) as covariates. Other hemodynamic 
parameters were analyzed by means of an ANCOVA model 
including the treatment group, location of cardiac defect 
and respective baseline value as covariates. The 6MWD in 
the hemodynamic substudy was analyzed posthoc by means 
of an ANCOVA model including the treatment group and 
baseline 6MWD as covariates.
Missing 6MWD values at week 16 were imputed as 0 m in 
the case of death. Otherwise, imputation of the missing week 
16 value was performed in 2 steps: first, the predicted prob-
ability of a missing value at each visit was estimated; then, the 
available 6MWD value at the prior visit was adjusted with this 
estimation. Imputation rules for all end points are provided in 
the online-only Data Supplement.
SAS® software, version 9.3 (SAS Institute, Cary, NC, USA) 
was used for the statistical analysis and the reporting of clini-
cal data.
RESULTS
Patients were screened in 71 centers across 26 coun-
tries. The number of patients enrolled at each cen-
ter is provided in Table I in the online-only Data 
Supplement. The first patient visit was in April 2013 
and the last patient visit was in December 2016. In 
total, 226 patients were randomized to macitentan 
(n=114) or placebo (n=112), including 20 patients with 
Down syndrome (10 per treatment group). Overall, 221 
patients completed 16 weeks of treatment (macitentan 
n=111; placebo n=110) (Figure 1). In the hemodynamic 
substudy, 39 patients were randomized to macitentan 
(n=20) or placebo (n=19), all of whom completed the 
substudy (Figure I in the online-only Data Supplement).
In the overall study, the baseline characteristics 
were generally well matched between the treatment 
groups (Table  1). The majority of patients were 
from Asia-Pacific nations or Eastern Europe (40.3% 
and 23.0%, respectively). There was an imbalance 
between treatment groups in age distribution, with a 
higher percentage of patients in both the older (≥56 
years) and younger (12–17 years) age categories in the 
macitentan group (9.6 and 11.4%, respectively) as com-
pared with placebo (4.5 and 1.8%, respectively). The 
majority of patients were in WHO FC II (59.7%) and the 
remaining patients (40.3%) were in WHO FC III. Most 
patients had post-tricuspid defects (78.3%) and the ma-
jority of patients had isolated ventricular septal defects 
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(52.7%). Complex cardiac defects were present in 24.3% 
of patients, with 40% of these having isolated patent 
ductus arteriosus and 27.3% having a partial/complete 
atrioventricular septal defect. At baseline, 27.4% of pa-
tients were taking PDE-5 inhibitors and had been receiv-
ing these for a median duration of 12.6 months. Baseline 
characteristics of patients in the hemodynamic substudy 
were generally comparable to those in the overall study. 
Exceptions include differences in age (with the substudy 
only enrolling patients aged ≥18 years), geographical re-
gion and defect complexity and the exclusion of patients 
with Down syndrome from the substudy (Table II in the 
online-only Data Supplement).
Primary End Point
At week 16, the 6MWD had increased from baseline by a 
mean±SD of 18.3±84.4 m in the macitentan group and 
19.7±53.0 m in the placebo group. The least-squares 
mean difference (95% CL) for the change from baseline 
to week 16 between macitentan and placebo was -4.7 
m (-22.8, 13.5; P=0.612) (Table 2 and Figure 2). The pro-
portion of patients with an improvement in 6MWD at 
week 16 (change from baseline >0 m) was 72.8% in the 
macitentan group and 65.2% in the placebo group. The 
difference in exercise capacity between treatment groups 
was consistent in all prespecified subgroups, as indicated 
by nonsignificant P values for interaction (Figure II in the 
online-only Data Supplement). Posthoc analyses showed 
that the difference between treatment groups was also 
consistent regardless of whether patients had simple or 
complex cardiac defects (P value for interaction 0.89). 
The treatment effect was also consistent across gender 
subcategories (P value for interaction 0.788) (posthoc 
analysis) (Figure III in the online-only Data Supplement). 
A posthoc analysis showed that the treatment effect 
of macitentan on change from baseline to week 16 
in 6MWD was similar for patients with and without a 
hemoglobin decrease of ≥ 2 g/dL from baseline to EOT 
(Table III in the online-only Data Supplement).
Secondary and Exploratory End Points
WHO FC improved from baseline to week 16 in 8.8% 
and 14.3% of patients in the macitentan and placebo 
groups, respectively (odds ratio, 0.53; 95% CL, 0.23, 
1.24) (Table 2). Worsening of WHO FC from baseline to 
week 16 was reported for 1 patient in each treatment 
group. There were no relevant trends in change from 
baseline to week 16 in the Borg dyspnea index between 
the macitentan and placebo groups. At baseline, the 
mean±SD NT-proBNP level was 693±1135.5 pg/mL 
and 893±2320.8 pg/mL in the macitentan and placebo 
groups, respectively. At end of treatment, the geomet-
ric mean (95% CL) NT-proBNP level decreased to 88.7% 
(80.0, 98.3) of the baseline value (mean decrease from 
baseline of 88 pg/mL) in the macitentan group and 
increased to 109.2% (96.5, 123.6) of the baseline val-
ue (mean increase from baseline of 72 pg/mL) in the 
placebo group (ratio of geometric means, 0.80; 95% 
CL, 0.68, 0.94) (Table 2). The placebo-corrected mean 
(95% CL) treatment effect of macitentan on SpO2 at 
rest was 0.8% (-0.3, 2.0). SpO2 was also measured im-
mediately after completion of the 6MWD; at this time-
point, the placebo-corrected mean (95% CL) treatment 
effect of macitentan was 2.0% (-0.7, 4.7) (Table 2).
Figure 1. Patient disposition. 
Patients were considered to have completed the study if they completed the 30-day safety follow-up period and Week 16 assessments, regardless of premature 
study treatment discontinuation. *The 3 patients who discontinued macitentan treatment prior to week 16 did not complete the study. †The 2 patients who 
discontinued placebo treatment prior to week 16 did complete the study. ‡The patient did not fulfill the inclusion criteria.
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Table 1. Patient Characteristics at Baseline*
Characteristic Macitentan n=114 Placebo n=112 All patients N=226
Female, n (%) 82 (71.9) 68 (60.7) 150 (66.4)
Age, y
  Median (range) 33 (12, 82) 31 (13, 62) 32 (12, 82)
  Distribution, n (%)
   12–17 13 (11.4) 2 (1.8) 15 (6.6)
   18–55 90 (78.9) 105 (93.8) 195 (86.3)
   ≥56 11 (9.6) 5 (4.5) 16 (7.1)
Geographic region, n (%)
  Asia-Pacific 47 (41.2) 44 (39.3) 91 (40.3)
  Eastern Europe 25 (21.9) 27 (24.1) 52 (23.0)
  Western Europe-Israel 21 (18.4) 18 (16.1) 39 (17.3)
  Latin America 19 (16.7) 18 (16.1) 37 (16.4)
  North America 2 (1.8) 5 (4.5) 7 (3.1)
Time from ES diagnosis, y, median (range) 5.28 (0.0, 59.4) 4.02 (0.0, 51.2) 4.65 (0.0, 59.4)
Down syndrome, n (%) 10 (8.8) 10 (8.9) 20 (8.8)
WHO functional class, n (%)†
  II 69 (60.5) 66 (58.9) 135 (59.7)
  III 45 (39.5) 46 (41.1) 91 (40.3)
6-minute walk distance, meters 368.7±74.5 380.3±76.3 374.5±75.4
SpO2 at rest, % 84.4±5.6 85.2±5.1 84.8±5.4
PDE-5 inhibitors
  n (%) 35 (30.7) 27 (24.1) 62 (27.4)
  Time from initiation, months, median (range) 12.8 (1.1, 79.3) 11.3 (1.0, 101.4) 12.6 (1.0, 101.4)
Location of cardiac defect, n (%)
  Pretricuspid 29 (25.4) 20 (17.9) 49 (21.7)
  Posttricuspid 85 (74.6) 92 (82.1) 177 (78.3)
Simple cardiac defect, n (%) 91 (79.8) 80 (71.4) 171 (75.7)
Complex cardiac defect, n (%)‡ 23 (20.2) 32 (28.6) 55 (24.3)
Right heart catheterization
  Mean PAP, mm Hg 77.4±15.1 79.9±17.3 78.7±16.2
  Mean RAP, mm Hg 7.9±5.2 7.7±4.5 7.8±4.9
  Mean PVR, dyn·sec/cm5 1807.5±792.8 1828.1±937.4 1817.7±865.9
  Mean LAP, LVEDP or mean PAWP, mm Hg§ 8.9±3.6 9.4±3.8 9.2±3.7
Hemoglobin, g/dL 18.5±2.83 19.0±2.66 18.7±2.75
ES indicates Eisenmenger syndrome; LAP, left atrial pressure; LVEDP, left ventricular end diastolic pressure; PAWP, pulmonary 
artery wedge pressure; PAP, mean pulmonary arterial pressure; PDE-5, phosphodiesterase type-5; PVR, pulmonary vascular 
resistance; RAP, right atrial pressure; SpO2, oxygen saturation; and WHO, World Health Organization.
*Plus–minus values are mean±standard deviation.
For time from ES diagnosis, data were missing for 2 patients in the macitentan group and 3 in the placebo group (a total of 
5 patients with missing data). For mean PAP, PVR, and mean LAP/LVEDP/mean PAWP, data were missing for 2 patients in the 
macitentan group and 1 in the placebo group (a total of 3 patients with missing data). For mean RAP, data were missing for 
11 patients in the macitentan group and 11 in the placebo group (a total of 22 patients with missing data).
†The WHO functional class ranges from I to IV, with higher numbers indicating greater functional limitations. There were no 
patients in WHO functional class I or IV enrolled in the study.
‡Twenty-two patients with an isolated patent ductus arteriosus, 15 patients with a partial/complete atrioventricular septal 
defect, 4 patients with an atrial septal defect and partial or total anomalous venous return, 14 patients classified as “other” 
(defined as isolated aortopulmonary window and combinations of other cardiac lesions, eg, ventricular septal defect plus patent 
ductus arteriosus).
§If more than 1 parameter was measured in the same patient, only 1 is displayed using the following order: mean LAP > 
LVEDP > mean PAWP.
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Exploratory End Points in the 
Hemodynamic Substudy
At week 16, the geometric mean PVRi decreased to 
85.3% of the baseline value in the macitentan group 
(corresponding to a mean decrease from baseline of 
410 dyn·sec/cm5/m2) and increased to 101.1% of the 
baseline value in the placebo group (corresponding to 
a mean increase from baseline of 79 dyn·sec/cm5/m2) 
(ratio of geometric means, 0.87; 95% CL, 0.73, 1.03) 
(Table 3, Figure 3). At week 16, the mean±SD systemic 
vascular resistance index decreased from baseline by 
376±910.4 dyn·sec/cm5/m2 in the macitentan group and 
increased from baseline by 11±1119.1 dyn·sec/cm5/m2 
in the placebo group (least-squares mean difference, 
-410 dyn·sec/cm5/m2; 95% CL, -953, 133). For all other 
cardiac hemodynamic parameters measured, there were 
no differences between treatment groups in the change 
from baseline to week 16 (Table 3). Posthoc analysis of 
the 6MWD for patients enrolled in the hemodynamic 
substudy showed a mean increase from baseline to week 
16 of 34.1 m in the macitentan group and 3.5 m in the 
placebo group (least-squares mean difference, 24.9 m; 
95% CL, -9.1, 59.0) (Table  3 and Figure  3). The pro-
portion of patients in the hemodynamic substudy with 
an improvement in 6MWD at week 16 (change from 
baseline >0 m) was 85.0% in the macitentan group and 
57.9% in the placebo group.
Safety
An overview of adverse events is presented in Table 4. 
Two patients in each treatment group had at least 1 
adverse event that led to premature discontinuation 
of study treatment. Treatment-emergent serious ad-
verse events were reported in 7 macitentan-treated pa-
tients (6.1%) and 2 placebo-treated patients (1.8%). 
Eight patients were hospitalized due to serious adverse 
events in the study: 6 in the macitentan group (1 for a 
nervous system disorder, 3 for cardiac disorders, and 
2 for infection) and 2 in the placebo group (both for 
cardiac disorders). One patient died (in the macitentan 
group); this death was due to respiratory failure and 
was considered unrelated to the study treatment.
Table 2. Primary, Secondary and Exploratory Efficacy End Points*
Endpoints
Macitentan Placebo
Treatment effect 
(95% CL)
Baseline
n=114
Postbaseline
n=114 Change
Baseline
n=112
Postbaseline
n=112 Change
Primary end point
  6-minute walk distance, m† 368.7±74.5 
(155 – 523)
387.1±101.8  
(0 – 547)
18.3±84.4 380.3±76.3 
(90 – 501)
399.9±79.5  
(57 – 534)
19.7±53.0 -4.7 (-22.8, 13.5)
P=0.612
Secondary end points
  WHO FC, n (%)‡
   I - 3 (2.6) Improved:
10 (8.8)
 
 
- 1 (0.9) Improved:
16 (14.3)
 
 
0.53 (0.23, 1.24)
   II 69 (60.5) 72 (63.2) 66 (58.9) 79 (70.5)
   III 45 (39.5) 38 (33.3) 46 (41.1) 32 (28.6)
   IV - 1 (0.9) - -
Exploratory end points
  NT-proBNP, pg/mL§# 693±1135.5 605±994.5 -88±537.2
88.7 (57.7)‖
893±2320.8 965±1951.6 72±1253.5
109.2 (70.5)‖
0.80 (0.68, 0.94)
  SpO2 at rest, %**†† 84.3±5.6 85.4±5.8 1.1±4.0 85.2±5.1 85.4±5.6 0.2±4.5 0.8 (-0.3, 2.0)
  SpO2 at 0 mins after 
6-minute walk test, %**‡‡
68.1±13.1 69.2±12.4 1.1±9.4 70.9±10.3 70.0±12.3 -0.9±10.7 2.0 (-0.7, 4.7)
CL indicates confidence limit; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SpO2, oxygen saturation; and WHO FC, World Health Organization functional class.
*Plus–minus values are mean±standard deviation. Post-baseline values were collected at end of treatment for NT-proBNP and at week 16 for all other endpoints. 
No imputation rules were planned for exploratory efficacy endpoints of the overall study; patients with missing values at baseline or week 16/end of treatment are 
excluded from these analyses.
†The primary end point was analyzed in the intention-to-treat population. Missing values were imputed for three patients at week 16 (all in the macitentan arm). 
The range in 6MWD values is reported in parentheses at baseline and week 16. The treatment effect expressed as the least-squares mean difference (macitentan 
minus placebo) for the change from baseline to week 16 in 6MWD was calculated by analysis of covariance, including treatment group, Down syndrome status, 
baseline WHO functional class and baseline 6MWD as covariates.
‡The treatment effect expressed as the odds ratio (macitentan:placebo) at week 16 was calculated using logistic regression, including treatment group and 
location of cardiac defect as covariates. Missing values were imputed for 2 patients.
§The treatment effect expressed as the ratio (macitentan:placebo) of geometric means was calculated by analysis of covariance on the log transformed ratio (end 
of treatment/baseline), including treatment group, location of cardiac defect and log transformed baseline values as covariates.
#Data were missing for 8 patients in the macitentan group and 8 patients in the placebo group.
‖For NT-proBNP, changes were expressed as a percentage of the baseline value (geometric mean [geometric coefficient of variation]).
**The treatment effect is expressed as mean (95% CL).
††Data were missing for 2 patients in the macitentan group.
‡‡Data were missing for 4 patients in the macitentan group and 1 patient in the placebo group.
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A mean decrease in hemoglobin of -1.04 g/dL from 
baseline up to week 16/EOT was observed in the maci-
tentan group, which occurred primarily within the first 
4 weeks of treatment and was maintained thereafter 
(Table 4). In the placebo group, hemoglobin values re-
mained stable from baseline up to week 16/EOT (mean 
change of 0.12 g/dL). One patient in each treatment 
group had an increase in alanine transaminase or as-
partate transaminase above 3 times the upper limit of 
normal, and this led to treatment discontinuation in the 
placebo group. The increase in the macitentan group 
was confirmed to be a false-positive signal by the central 
laboratory and treatment was continued. A decrease of 
more than 10% in SpO2 at any time from baseline up 
to 30 days after study treatment discontinuation was 
reported for 6 patients (5.3%) in the macitentan group 
and 10 patients (8.9%) in the placebo group.
Open-Label Extension Study
A total of 217 patients (97% of the patients who com-
pleted the double-blind study) entered the open-label 
extension study; 202 had an assessment at month 
6 (data collected up to 7th June 2017). In an analysis 
of these 202 patients (n=100 for macitentan, n=102 
for placebo/macitentan) from this open-label study, 
which is based on observed data only, patients who 
received double-blind placebo followed by open-label 
macitentan had a mean±SD improvement in 6MWD of 
27.1±43.4 m from baseline to month 6. This improve-
ment was maintained at month 12, with a mean±SD 
increase in 6MWD of 24.5±55.6 m from the open-
label baseline. Patients who received macitentan in the 
double-blind study followed by open-label macitentan 
had a mean±SD improvement in 6MWD of 6.0±55.8 m 
from baseline in the open-label extension to month 12.
Figure 2.  Primary end point of change from baseline to week 16 in 
6-minute walk distance. 
6MWD indicates 6-minute walk distance; and CL, confidence limit. Mean (plus 
95% CL) change from baseline to week 16 in 6MWD is shown for macitentan 
and placebo in the intention-to-treat population with missing values imputed. 
The 6MWD increased from baseline by a mean of 18.3 m in the macitentan 
group and 19.7 m in the placebo group. The macitentan minus placebo 
least-squares mean difference (treatment effect) was -4.7 m (95% CL -22.8 to 
13.5; P=0.612) calculated using an analysis of covariance model including the 
treatment group, Down syndrome (yes/no), WHO functional class at baseline 
(II versus III/IV), and baseline 6MWD as covariates. Missing values were im-
puted for 3 patients.
Table 3. Exploratory Hemodynamic End Points and 6MWD in the Hemodynamic Substudy*
Endpoints
Macitentan Placebo
Treatment effect 
(95% CL)n Baseline Week 16 Change n Baseline Week 16 Change
mPAP, mm Hg† 19 77.5±11.6 71.1±13.6 -6.4±8.2 17 79.0±15.8 75.5±16.3 -3.5±9.6 -3.0 (-8.8, 2.7)
mRAP, mm Hg† 19 6.1±3.8 7.2±4.5 1.1±4.2 16 6.7±3.8 6.7±3.6 0.0±3.6 0.8 (-1.7, 3.3)
Qpi, L/min/m2†‡ 18 2.3±0.88 2.4±0.61 0.09±0.88 17 2.4±0.65 2.2±0.68 -0.12±0.32 0.17 (-0.19, 0.53)
Qsi, L/min/m2†‡ 16 2.6±0.58 2.7±0.54 0.15±0.74 17 2.8±1.47 2.5±1.03 -0.31±1.67 0.25 (-0.36, 0.85)
Qpi/Qsi ratio† 16 0.98±0.73 0.94±0.32 -0.05±0.80 17 0.98±0.46 1.01±0.50 0.04±0.35 -0.09 (-0.38, 0.20)
PVRi, dyn·sec/cm5/m2§ 20 2821±1321 2411±1011 -410±752
85 (36)‖
19 2776±1455 2855±1515 79±491
101 (21)‖
0.87 (0.73, 1.03)
SVRi, dyn·sec/cm5/m2† 16 2757±889.4 2381±524.2 -376±910.4 16 2789±1229.1 2801±1010.2 11±1119.1 -410 (-953, 133)
PVRi/SVRi† 16 1.08±0.56 1.05±0.73 -0.03±0.49 16 1.08±0.65 1.06±0.64 -0.03±0.83 0.01 (-0.44, 0.46)
6WMD, m#‡ 20 359.0±69.8 
(170 – 484)
393.1±60.7 
(300 – 510)
34.1±57.4 19 382.9±91.5 
(90 – 501)
386.4±96.6 
(57 – 482)
3.5±51.6 24.9 (−9.1, 59.0)
6WMD indicates 6-minute walk distance; CL, confidence limit; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; PVRi, pulmonary 
vascular resistance index; Qpi, pulmonary flow index; Qsi, systemic flow index and SVRi, systemic vascular resistance index.
*Plus–minus values are mean±standard deviation. No imputation rules were planned for hemodynamic parameters other than PVRi in the substudy. Patients with 
missing values at baseline or week 16/end of treatment were excluded from the analyses.
†The treatment effect expressed as the least-squares mean difference (macitentan minus placebo) was calculated by analysis of covariance, including treatment 
group, location of cardiac defect and baseline value as covariates.
‡Posthoc analyses.
§The treatment effect expressed as the ratio (macitentan:placebo) of geometric means was calculated by analysis of covariance on the log transformed ratio (week 
16/baseline), including treatment group, location of cardiac defect and log transformed baseline value as covariates.
‖For PVRi, changes were expressed as a percentage of the baseline value (geometric mean [geometric coefficient of variation]).
#The treatment effect is the least-squares mean difference (macitentan minus placebo) calculated by analysis of covariance, including treatment group and 
baseline 6MWD as covariates. The range in 6MWD values is reported in parentheses at baseline and week 16. There were no patients with missing 6MWD data at 
week 16 in the hemodynamic substudy.
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DISCUSSION
In the MAESTRO study, macitentan did not have an ef-
fect on the primary end point of change from baseline 
to week 16 in 6MWD compared with placebo in pa-
tients with ES. In addition, no relevant trends with ma-
citentan were observed for the secondary end points. 
Among the exploratory end points, macitentan reduced 
NT-proBNP levels in the main study cohort and im-
proved PVRi and 6MWD in the hemodynamic substudy. 
There were no specific safety concerns with the use of 
macitentan in patients with ES; the safety profile was 
consistent with that in other PAH etiologies.23
In contrast to results from the BREATHE-5 study,5 
ES patients treated with an ERA in MAESTRO had less 
robust improvement in 6MWD; furthermore, a large 
improvement was seen in placebo-treated patients, 
limiting the overall treatment effect of macitentan. The 
placebo effect was consistent across all prespecified 
subgroups and was unexpected, given that the MAE-
STRO population was predominantly untreated. This 
placebo effect also runs contrary to results from most 
randomized controlled trials of targeted therapies in 
PAH,5,23,25–38 regardless of concomitant disease state or 
WHO FC. The reasons for the large placebo effect, and 
the overall lack of treatment effect of macitentan on 
the primary end point, are not clear, but a number of 
factors were considered and are discussed below.
In MAESTRO, enrollment of patients with com-
plex cardiac defects, WHO FC II, Down syndrome and 
PDE-5i therapy at baseline resulted in a more hetero-
geneous population compared with BREATHE-5.5 In 
the latter trial, all patients had simple cardiac defects, 
WHO FC III, were treatment-naive and did not have 
Down syndrome.5 Of note, mortality rates for WHO 
FC II patients with ES are considerable8 and therefore 
their inclusion in MAESTRO is of fundamental impor-
tance. We explored whether these population differ-
ences influenced the treatment effect on the primary 
end point in MAESTRO. With regards to the inclusion 
of patients receiving PDE-5i, PAH studies have dem-
onstrated that the presence of background therapy 
can attenuate the treatment effect on exercise capac-
ity.39 In MAESTRO, however, the difference in exercise 
capacity between treatment groups was consistent 
across subgroups defined according to background 
therapy. In relation to the inclusion of patients with 
Down syndrome, the beneficial effects of PAH-specific 
therapy on 6MWD may be less pronounced in this 
population,40 and their cooperation during exercise 
testing may not be consistent. As enrollment of Down 
syndrome patients may affect assessment of exercise 
capacity, their inclusion in the study was extensively 
discussed by the steering committee, and efforts were 
made to adapt the standard 6MWT procedures and 
familiarization components to the needs of the Down 
syndrome patient. Although the sample size was small 
for Down syndrome patients, the data indicate that 
including these patients did not compromise the pri-
mary end point result. Similar consistency in results 
was noted between the subset of patients with WHO 
FC II as compared with WHO FC III.
We investigated whether there was variability in the 
performance of the 6MWT and if this impacted the 
primary end point result. In our study, patients with 
variance in screening 6MWD >15% were excluded, 
A B
Figure 3. Percent of baseline PVRi at Week 16 and change in 6MWD from baseline to week 16 in the hemodynamic substudy. 
6MWD indicates 6-minute walk distance; PVRi, pulmonary vascular resistance index; and CL, confidence limit. A, Unadjusted geometric mean PVRi (95% CL) at 
week 16, expressed as a percentage of baseline, is shown for the macitentan and placebo groups in the intention-to-treat population with missing values imputed. 
The geometric mean PVRi decreased to 85.3% of the baseline value in the macitentan group and increased to 101.1% of the baseline value in the placebo group. 
The macitentan:placebo ratio of geometric means (treatment effect) was 0.87 (95% CL, 0.73–1.03) calculated using an analysis of covariance model on the log 
transformed ratio (week 16/baseline), including the treatment group, location of cardiac defect and PVRi at baseline as covariates. Missing values were imputed 
for 4 patients. B, Mean (plus 95% CL) change from baseline to week 16 in 6MWD in the hemodynamic study (posthoc analysis) is shown for the macitentan and 
placebo groups in the intention-to-treat population. There were no patients with missing data. The 6MWD increased from baseline by a mean of 34.1 m in the 
macitentan group and 3.5 m in the placebo group. The macitentan minus placebo least-squares mean difference (treatment effect) was 24.9 m (95% CL, -9.1 to 
59.0) calculated using an analysis of covariance model, including treatment group and baseline 6MWD as covariates.
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with intent to minimize variability in 6MWT perfor-
mance. Surprisingly, 36% of patients had a 6MWD at 
randomization that was lower (in some cases by more 
than 30 m) than the mean of their 2 screening tests. 
While site-specific variance in 6MWD testing was not 
noted among the larger study sites, we cannot exclude 
the possibility that the involvement of less-experienced 
centers may have impacted the performance of the 
6MWT. Interestingly, in the hemodynamic substudy (in 
which only participating centers with greater adult con-
genital heart disease catheterization experience were 
included) a favorable treatment effect on 6MWD and 
PVR was observed in the macitentan-treated group, 
whereas no placebo effect was detected; this suggests 
potential effects of improved adherence to anatomic 
and physiological entry criteria by substudy sites, refine-
ment of diagnosis by hemodynamic assessment within 
30 days of trial enrollment in the substudy as contrasted 
to a 5-year window for such within the main study, or 
that the 6MWT might have been performed in a more 
standard fashion in the substudy. However, it should be 
noted that the proportion of patients with a 6MWD at 
randomization that was lower than the mean of their 2 
screening 6MWTs was comparable between the overall 
study and the substudy.
We also investigated whether the decrease in hemo-
globin for macitentan-treated patients affected the pri-
mary end point result, given that reduced hemoglobin 
levels are associated with impaired exercise capacity.41 
However, posthoc analysis demonstrated that the treat-
ment effect of macitentan on 6MWD was comparable 
between patients with and without a hemoglobin de-
crease of ≥2 g/dL. In addition, there was no decrease in 
mean SpO2 following macitentan treatment. Given that 
the ratio of pulmonary blood flow (indexed pulmonary 
blood flow) to systemic blood flow (indexed systemic 
blood flow) also did not change with macitentan (ie, 
the intravascular shunt remained unchanged), the lack 
of fall in the systemic oxygen saturation (as reflected by 
the mean SpO2) does not lend support to an effect of 
hemoglobin on the primary end point result.
The large effect in the placebo arm on exercise ca-
pacity contributed significantly to the failure to achieve 
the primary end point in MAESTRO. During the study, 
gains in 6MWD may have resulted from familiariza-
tion with the 6MWT in a supervised clinical setting, 
or from adaptation to exercise and improved muscle 
strength. As ES patients are traditionally restricted 
from exercising, due to the risk of systemic vasodila-
tation in the context of markedly reduced pulmonary 
vasodilator reserve, training-related improvements in 
exercise capacity may be particularly pronounced in 
this population. It is important to note that the result-
ing increase in exercise capacity would occur equally 
in both treatment arms, contributing to the observed 
Table 4. Summary of Adverse Events and Abnormal Laboratory 
Findings*
 
Macitentan
N=114
Placebo
N=112
Patients with ≥1 treatment-emergent AE, 
n (%)
76 (66.7) 70 (62.5)
Patients with ≥1 treatment-emergent SAE, 
n (%)
7 (6.1) 2 (1.8)
Patients with ≥1 AE leading to 
discontinuation of study treatment, n (%)
2 (1.8) 2 (1.8)
Adverse event, n (%)†
  Headache 13 (11.4) 5 (4.5)
  Upper respiratory tract infection 11 (9.6) 7 (6.3)
  Bronchitis 6 (5.3) 3 (2.7)
  Dizziness 6 (5.3) 3 (2.7)
  Edema peripheral 5 (4.4) 4 (3.6)
  Right ventricular failure 4 (3.5) 1 (0.9)
  Fatigue 4 (3.5) 1 (0.9)
  Erythema 4 (3.5) 0
Serious adverse events, n (%)
  Right ventricular failure 3 (2.6) 0
  Pneumonia 2 (1.8) 0
  Acute kidney injury 1 (0.9) 0
  Atrial fibrillation 1 (0.9) 1 (0.9)
  Dizziness 1 (0.9) 0
  Endocarditis 1 (0.9) 0
  Respiratory failure 1 (0.9) 0
  Septic shock 1 (0.9) 0
  Transient ischemic attack 1 (0.9) 0
  Chronic cardiac failure 0 1 (0.9)
Other AEs of interest, n (%)‡
  AEs related to anemia 6 (5.3) 1 (0.9)
  AEs related to edema and fluid overload 8 (7.0) 6 (5.4)
  AEs related to hypotension 3 (2.6) 3 (2.7)
Laboratory findings of interest§
  Change from baseline to week 16/
end of treatment in hemoglobin, g/dL, 
mean±SD
-1.04±1.37‖ 0.12±1.22‖
  Hemoglobin decrease from baseline 
≥2 g/dL
41 (36.0) 10 (8.9)
  ALT or AST ≥3 x ULN 1 (0.9) 1 (0.9)
SpO2 decrease from baseline >10%, n (%) 6 (5.3) 10 (8.9)
AE indicates adverse event; ALT, alanine transaminase; AST, aspartate 
transaminase; SAE, serious adverse event; SD, standard deviation; SpO2, oxygen 
saturation; and ULN, upper limit of normal.
*Patients could have >1 event. Adverse events and serious adverse events 
were reported from study drug initiation until 30 days after study drug 
discontinuation, and were reported at the discretion of the investigator.
†Adverse events are listed for those that occurred in more than 3 patients in 
the macitentan group.
‡AEs of special interest related to anemia, edema and fluid overload, and 
hypotension were predefined in the analysis plan.
§Data are n (%) unless otherwise indicated.
‖Data were missing for 1 patient in the macitentan group and 3 patients in 
the placebo group (a total of 4 patients with missing data).
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effect in the placebo arm and potentially masking the 
treatment effect of macitentan in the active arm; an 
additive effect of drug therapy on top of the increased 
function resulting from physical conditioning or fa-
miliarization with the 6MWT would not be expected 
during the 16-week study period. This is particularly 
true in the ES population, as PAH therapies have sys-
temic vasodilator potential, which may increase right-
to-left shunting and exaggerate cyanosis, hampering 
an additional increase in function due to therapy. We 
recognize that other factors may have contributed to 
the increased functional ability of patients with ES 
in our study; trial enrollment and clinical care within 
the study centers alone may also have improved care. 
Of note (and recognizing their limitations), a number 
of posthoc analyses were performed and all failed to 
demonstrate meaningful differences in the treatment 
effect between the patient subgroups tested. It is pos-
sible that certain physiological and clinical findings, in-
cluding decrease in NT-proBNP in macitentan-treated 
patients in the main MAESTRO study, decrease in PVR 
and increase in 6MWD in macitentan-treated patients 
in the hemodynamic substudy, and the improvement 
in placebo-treated patients switched to macitentan in 
the open-label extension study, may help shed light on 
disease mechanisms in ES.
The safety and tolerability of macitentan in patients 
with ES was congruent with the known safety profile 
of macitentan in patients with PAH.23,42 This included a 
higher incidence of headaches with macitentan versus 
placebo and a comparable low incidence of edema 
between the treatment arms. In addition, the observed 
decrease in hemoglobin following macitentan 
treatment is consistent with the previously reported 
safety profile of the drug. Similar to the BREATHE-5 
study with bosentan,5 treatment with macitentan did 
not adversely affect SpO2. As previously discussed, this 
can be explained by the fact that macitentan had a 
similar effect on both the systemic and pulmonary 
circulations and, therefore, a limited impact on the 
net right-to-left shunt.
In conclusion, macitentan did not show superiority 
over placebo on the primary end point of change from 
baseline to week 16 in exercise capacity in patients 
with ES. There were no safety concerns with the use 
of macitentan in patients with ES. There were several 
novel elements to the study, including the enrollment 
of patients with Down syndrome and anatomically- 
classified complex cardiac defects. MAESTRO may 
serve as a reference for future trials in patients with 
Eisenmenger syndrome.
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